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Introduction
From 13 February to 27 June 1997, 447 cases of
gonococcal conjunctivitis were identified by
Communicable Disease and Public Health
Centres and Community Clinics in the Northern
Territory (NT), Western Australia (WA) and
South Australia (SA). The outbreak involved
Aboriginal communities predominantly in Central
Australia (which included the western Alice
Springs region, NT, the Ngaanyatjarra central
desert area and the Pitjantjatjara Lands of SA)
and the Kimberley region in WA.  This was the
first outbreak recorded in the Kimberley region. It
is not yet known whether the Kimberley cases
were part of the larger Central Australian
outbreak or whether they represented a separate
and unrelated outbreak.
Gonococcal conjunctivitis causes considerable
morbidity in Aboriginal communities in Central
Australia during outbreaks.1,2,3,4,5 The disease is
characterised by acute painful conjunctivitis with
rapid non-sexual transmission between
individuals caused by person to person contact.
Bushflies may act as a mechanical vector of
Neisseria gonorrhoeae. There have been five
previously documented gonococcal conjunctivitis
outbreaks in Central Australia. These are
summarised in Table 1.
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Table 1 Time and size of reported gonococcal
conjuntivitis outbreaks in Central
Australia
Year of outbreak Cases* Period of outbreak
1934 91            -
1981 35 May to June
1986/87 140+ November to May
1991 432 January to July
1992 62+ April to July
* Includes both clinical and laboratory confirmed cases
Similar environmental factors leading up to and
during previous outbreaks were observed with this
outbreak. These factors included above average
summer rainfall preceding the outbreak,  summer
changing to winter temperatures, an increase in the
percentage of Haemophilus sp. isolates from eye
swabs and increased fly numbers at the start of the
outbreak. None of the outbreaks were
characterised by an increase in notifications of
sexually transmitted gonorrhoea in the time period
preceding the outbreak.
Methods
Case definition
A clinical illness was defined as intense
inflammation of the conjunctivae, copious purulent
discharge with or without periorbital oedema.  A
clinical case was confirmed when N. gonorrhoeae
was isolated on culture, detected by PCR or Gram
negative diplococci were seen in microscopy.
Unconfirmed clinical cases were included in this
analysis if there was a laboratory confirmed case
notified from the same community. Date of onset
was defined as the date on which the eye swab
confirming the diagnosis was taken.
Collection of data
Patient information including age, gender, date of
onset of illness and address was obtained from
Disease Control Centres in Alice Springs NT and
Adelaide SA; Goldfields Public Health Services -
Boulder, WA; Kimberley Public Health Unit -
Derby, WA; Western Diagnostic Pathology - Alice
Springs, NT and Pathology - Alice Springs
Hospital (ASH), NT. Information on the number of
clinical unconfirmed cases, spread of disease and
fly density was obtained from Community Health
Clinics in Central Australia. Population
demographic statistics were obtained from
Nganampa Health Council, Ngaanyatjarra Health
Service and Rural Health - Alice Springs, Territory
Health Services (THS). Rainfall and temperature
data were obtained from the Bureau of
Meteorology - Darwin and Alice Springs Regional
Offices NT and WA. Information regarding the
number of clinical cases was not obtained from the
Kimberley.
Laboratory Investigation
N. gonorrhoeae strains from Central Australia
were sent to the Prince of Wales Hospital, Sydney,
for serotyping, auxotyping and MIC testing and
included 89 eye, 34 genital and 2 joint isolates.
Records at the Pathology Laboratory, ASH, were
examined to determine the percentage of
Haemophilus sp. identified from eye swabs
between June 1996 and June 1997 and also the
number of cases of disseminated gonococcal
infection (DGI) between 1 August 1995 and 18
July 1997. DGI was defined as the isolation of N.
gonorrhoeae from a sterile site e.g. joint fluid.
Results
Number of cases
There were 242 confirmed cases (including 5
reinfection cases) and 205 unconfirmed cases of
gonococcal conjunctivitis for a total of 447 cases.
Of the confirmed cases 120 were culture positive,
53 PCR positive and 69 microscopy positive. The
NT had 121, WA 105 and SA 16 confirmed cases.
There appears to have been two epidemics during
the outbreak (Figure 1). The smaller epidemic
peaked in the Kimberley during March before a
larger epidemic, involving many more
communities in Central Australia, peaked in May.
Figure 1 242 laboratory confirmed cases of
gonococcal conjunctivitis by week
and geographic region, Feb-June ‘97
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Age distribution of cases
Over three quarters of the confirmed cases were
children under 10 years old with the greatest
number recorded in the 5 to 9 group (Table 2).
The youngest child was four months old.
Table 2 Age distribution of confirmed cases
Age group (yrs) Cases % of cases
0 to 4 73 30.2
5 to 9 114 47.1
10 to 14 35 14.5
15 and over 12 4.9
Unknown 8 3.3
Total 242 100.0
Gender
There were 113 males and 129 females with
confirmed infection.
Rainfall
The Giles Meteorological Station is in WA
approximately 150 kms North of  the junction of
the WA, NT and SA borders. This station was
one of the closest to the communities which
were involved in the start of the outbreak. The
rainfall at Giles in December was above average
and there was substantial rainfall in January and
February preceding the outbreak (Figure 2). The
first cases of the outbreak appeared in the middle
of February. Alice Springs received 80 mm of
rain in January and 242 mm in February. The
Kimberley region received 136 mm of rain in
January and 274 mm in February.
Figure 2 Number of cases compared to the
monthly rainfall at Giles, January
1996 to June 1997
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Temperature
The mean daily minimum temperature at Giles in
February was 24.7°C (Figure 3) at the start of the
outbreak and was below 10°C in June at the end
of the epidemic. The mean daily maximum
temperature in February was 36°C at the start of
the epidemic. Typical summer temperatures
preceded the outbreak.
Figure 3 Number of cases compared to the
mean daily minimum temperatures at
Giles for each month, June 1996 to
June 1997
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Sexually transmitted gonorrhoea in Central
Australia
There was no increase in the notifications of
sexually transmitted N. gonorrhoeae preceding the
outbreak. The notification information indicated
that sexually transmitted disease was endemic at
nearly the same level all year round.
Proportion of Haemophilus sp. isolates from
eye swabs received at Alice Springs Hospital
Using Haemophilus sp. as an indicator of the
amount of general bacterial/viral eye disease in
communities the total number of Haemophilus sp.
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identified each month from eye swabs was
expressed as a proportion of the monthly total
number of eye swabs received.  The highest
proportion (47%) of Haemophilus sp. during the
thirteen months occurred in March 1997.  The
mean monthly proportion was 33%. There was a
gradual increase in the proportion of eye disease
in which Haemophilus sp. was isolated at the start
of the outbreak.
There is some indication that conjunctivitis caused
by Haemophilus sp. is endemic all year and
Haemophilus conjunctivitis rises prior and during
gonococcal conjunctivitis outbreaks. This has
been observed in every previous outbreak and
possibly due to the same environmental/other
stimuli which promotes the gonococcal
transmission.
Fly density
Thirteen Central Australian communities involved
in the epidemic were contacted and asked when
they thought flies were at their worst and when the
flies decreased in number. Five communities
where the first gonococcal conjuntivitis index
cases appeared reported the flies were “terrible” in
February.  Ten communities reported that the flies
were at their worst in March and April. Four
communities had their worst flies in May. Fly
density was dramatically reduced in June.
Auxotyping, serotyping and MIC testing
from Central Australia
Fifty three eye isolates involved in the outbreak,
that have been fully typed, belonged to
auxotype/serovar class Wt/IB3. Fourteen STD
background isolates obtained during the outbreak
were typed and included six Wt/IB3 strains as
well as seven other types.  Two eye isolates not
involved in the outbreak, consisted of two
different strains which were not Wt/IB3. Two
joint isolates consisted of a Wt/IA4 strain and a
IB3 serovar (the Wt/IA4 strain was not involved
in the outbreak but included as a background
strain).  The majority of the eye isolates tested so
far have had a penicillin MIC of between 0.125
and 0.25 mg/L, with one isolate having a
penicillin MIC of 0.5 mg/L. All are classified as
sensitive to penicillin, but in the less sensitive
range.
Public health response
An alert was sent by Alice Springs Disease
Control to Central Australian communities (NT,
WA, SA) in March after several cases had been
reported. This alerted the communities to the
presence of current cases, urged that swabs and
cultures be taken and that procaine penicillin or
amoxycillin with probenecid be given. A second
alert was sent out in April. In May, with over 40
cases reported, a further alert was sent out which
included direction to treat household contacts, a
direction not explicitly stated in the Central
Australian Rural Practitioners Association
(CARPA) standard treatment manual. An alert
also went to all remote schools telling of the
outbreak and the need for treatment. The
outbreak, protocol and need to treat all
household contacts were discussed both at the
Central Australia Disease Control Coordinating
Committee (CADCCC) meeting/teleconference
on 9/5/97 and again at the CARPA Conference
on 10-11/5/97.
Public Health Unit staff in the Kimberley region
arrived at the affected community within 24
hours of the first notification (though not
necessarily the index case) of gonococcal
conjunctivitis. They then assisted local staff with
screening and treatment.
Discussion
The number of cases reported is undoubtedly an
underestimate of the true number of gonococcal
eye infections as not all patients presenting with
conjunctivitis had an eye swab and smear taken
for laboratory confirmation by either culture,
smear or PCR. Direct input from Central
Australian communities was invaluable in
obtaining a more accurate amount of clinical
disease that was treated. Delays in transport
resulted in the death of  N. gonorrhoeae in
swabs and confirmation of infection could only
be made from smear and PCR. All the
Kimberley cases were tested by PCR.
The sharp peak in the number of Kimberley
cases in Figure 1 is artefactual. When Public
Health Unit staff arrived at the community
many patients had been experiencing
symptoms of conjunctivitis for several days or
more. Cases had been observed during late
January and early February but no swabs had
been taken as gonococcal conjunctivitis had
not been suspected.
Fly counts were not performed in any
community and the subjective assessment of fly
numbers by staff may be inaccurate but the
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survey covered many communities and a
reasonable picture was obtained. There is
still insufficient evidence to determine
whether flies definitely contribute to the
spread of gonococcal conjunctivitis. Recent
studies in WA have shown that Chlamydia
trachomatis can survive in the crop of
bushflies, however, further work is still in
progress to ascertain whether the number of
organisms carried is sufficient to cause trachoma
(unpublished work by Dr. Ian Dadour,
entomologist).
The environmental factors present in this
outbreak were similar to previous outbreaks,
including: 1) heavy summer rainfall at least one
month before the first cases appeared, 2) a mean
daily minimum temperature above 20°C for the
first two months of the outbreak, 3) eye
infections caused by Haemophilus sp. increased
to the highest monthly percentage for the year
and 4) an extremely high fly population occurred
in February, March and April. Sexually
transmitted N. gonorrhoeae cases did not
increase before the outbreak.
Factors which contributed to the outbreak
include: a) N. gonorrhoeae can only survive in
warm moist conditions and will die rapidly in a
dry cold atmosphere. Survival of the organism
on fomites would have been optimal at the start
of the outbreak, rapidly decreasing as the
temperature dropped below 10°C. b) The
breeding conditions, including humidity and
temperature, for the bushfly were ideal9 just after
the rainfall in December and then deteriorated
markedly in June.  Bushfly pupae cannot survive
at all when the temperature fluctuates between
6°C and 18°C.  c) Small adult flies were present
(indicating a reduced larval stage) during the
outbreak and there was extreme pressure for
available protein necessary for the breeding
cycle and moisture/food for survival. Flies were
theoretically attracted to moist, pussy eyes and
became ‘sticky’ flies.
In addition to these factors there is a large
reservoir of sexually transmitted N. gonorrhoeae
in remote Aboriginal communities in Central
Australia.7
Injectable penicillin or amoxycillin with
probenecid worked well during this outbreak to
eradicate gonococcal conjuntivitis. The highest
penicillin MIC recorded against the isolates of
N. gonorrhoeae causing this outbreak was 0.5
mg/L which lies in the less sensitive range.
Another possible site of N. gonorrhoeae, though
not necessarily involved in transmission to the
eye, is oropharyngeal carriage of the organism.
One investigator6 found three asymptomatic
oropharyngeal carriers of N. gonorrhoeae in the
1991 gonococcal conjuntivitis outbreak. Two of
these carriers were children under ten years of
age. During the same outbreak three individuals
had confirmed gonococcal conjunctivitis as well
as oropharyngeal carriage of N. gonorrhoeae . It
was thought there was autoinoculation of the
oropharynx via the nasolacrimal duct. In one
report gonococci were detected in the saliva of
pharyngeal carriers.10 Autoinoculation may also
occur from pussy eye to hand to mouth and
throat. There may be conjunctival
autoinoculation to a child’s throat and
transmission via droplet to another child’s eye.
The prevalence of pharyngeal carriage in
outbreaks of non-sexually transmitted
gonococcal conjunctivitis in Central Australia is
unknown.
Oropharyngeal carriage of N. gonorrhoeae is
more difficult to eradicate than uncomplicated
infections at other mucosal sites.8 Single dose
treatment with less effective antibiotic regimens
will achieve an approximate 70% cure rate. The
most highly effective single dose treatments are
likely to cure at least 80% of pharyngeal
infections, although the same treatments will cure
> 95% of uncomplicated anogenital gonorrhoea
infections. The failure to eliminate any
pharyngeal carriage which may be present has
three consequences: a) the probability of a
continuing reservoir of infection to further infect
the community; b) the possibility of recurrent
infection in the individual; and c) a possible
source of disseminated gonococcal infection
(DGI) in an individual.  DGI in a 3 year old boy
was documented as a complication in the 1991
epidemic.4  Two cases of DGI were diagnosed at
the ASH in May 1997. N. gonorrhoeae was
isolated from the joint fluid of a 14 year old boy
and a 26 year old woman. The isolate from the
boy was serovar IB3. Unfortunately the isolate
from the woman was not kept for testing. Both
of these patients had no history of sexually
transmitted N. gonorrhoeae at the time and both
lived in communities which were affected by the
outbreak.
There is a great deal of mobility of Aboriginal
people between communities. This contributes to
the spread of disease. Examination of dates of
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onset of disease figures and talking to staff at
community clinics has indicated that the
outbreak seemed to have started at the WA/NT
border and moved eastwards into the Alice
Springs region as well as down into the top of
SA.
There is the possibility of mini-outbreaks in
different communities. Auxotyping and
serotyping of gonococcal isolates from the
1986/87 and 1991 outbreaks identified four
different strains of gonococci in one outbreak
and four in the other. So far there has been only
one strain identified from the Central Australian
eye isolates obtained during this outbreak. There
were no organisms for typing from the
Kimberley. Two eye background isolates (not
contributing to the outbreak) were tested and
found to be different strains. As has happened in
previous outbreaks there were numerous
sexually transmitted N.gonorrhoeae background
strains and eight different strains were detected
in the sample tested preceding and during this
outbreak. It appears that different strains are
predominant during different times of the year
and any strain is capable of causing a
gonococcal outbreak.
Control measures
We have enough information to help predict
when an outbreak is likely to occur (see table 3)
and communities should monitor their
populations in these circumstances to detect
index cases. Central Australian outbreaks have
been occurring approximately every five years
since 1981. If a case is detected the relevant
Public Health and Disease Control Centres
should be notified immediately. Interstate
Disease Control Centres also need to be notified
so all adjacent communities can be informed of a
possible epidemic. Following the collection of
the specimen, including a direct smear, treatment
should be given to cases and their close contacts
prior to laboratory confirmation as some
specimens, due to transportation availability, can
take up to one week to reach the laboratory.
Direct smears are essential for a rapid diagnosis.
PCR is more sensitive than either culture or
smear but culture is essential for antibiotic
sensitivity monitoring.
Once the disease is established contact tracing
can become extremely difficult due to limited
local resources.  The disease is self limiting
when it becomes colder and the majority of
clinical cases have been treated, but sporadic
cases can still surface (note epidemic curve of
the Kimberley outbreak) and if conditions
become favourable a further epidemic could
eventuate. Treatment failures must be detected
rapidly. Community members must be educated
on the transmission of the disease from eye to
eye between children. Poor hygienic practices
have been observed in previous outbreaks e.g.
wiping an infected child’s eyes and then using
the same material to wipe another child’s face.4
Flies may act as a mechanical vector to establish
index cases from reservoirs of N. gonorrhoeae
and then, along with person to person
transmission, contribute to the spread of the
disease. However, fly control is virtually
impossible during the start of the outbreak
because of the extremely high population of
flies.
Early recognition and treatment of index cases
and identifying and treating contacts is currently
the only way of preventing an epidemic.
Strategies are in place to detect and treat
sexually transmitted N. gonorrhoeae in
communities. Until this reservoir of disease is
controlled gonococcal conjunctivitis is likely to
appear again. The role of oropharyngeal carriage
of N. gonorrhoeae has to be evaluated further.
Table 3 Factors which may predict
outbreaks of gonococcal
conjunctivitis
1. Heavy above average summer rainfall.
2. Mean daily elevated minimum temperature of
20°C following summer rain in early
autumn.
3. Increase in Haemophilus sp. eye infections.
4. Large fly populations.
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Editorial
The above article is a welcome review of
a recent outbreak of gonococcal
conjunctivitis and the discussion raises many
points regarding the disease, its transmission and
treatment to consider.  Most importantly,
however, it highlights to health care providers
the fact that childhood conjunctivitis may be
caused by Neisseria gonorrhoeae which is
highly contagious and requires systemic
antibiotics.  This is in contrast to the more
common causes of conjunctivitis - allergic, viral
and the non gonococcal bacterial, ie
Haemophilus influenzae, Streptococcus
pneumoniae, S. pyogenes and Staphylococcus
species which are usually treated by topical
antiseptics or in more severe case, topical
combination antibiotic drops or eye ointment1.
So, N. gonorrhoeae does need to be
considered in conjunctivitis especially in
areas where there is endemic high
prevalence of venereal gonorrhoeal disease
and environmental factors which may promote
spread to the eyes.  Swabs and cultures must be
taken to establish the diagnosis.  The NT Centre
for Disease Control (CDC) endorsed protocol
for individual management and public health
response is provided below.  It was being
prepared as the outbreak evolved and it was
formulated after consultation with various
centres involved in past outbreaks (eg in WA,
Alice Springs and Katherine) and after
examining a number of protocols. It generally
still reflects past informal NT CDC
control measures.
The paper supports that one notified case of non-
sexually transmitted gonococcal conjunctivitis
should be treated as a potential outbreak and
responded to as per the protocol including
treating household contacts or childcare or
school contacts.  Emphasising thorough hand
and face washing and making sure that there are
provisions for this in affected households or
schools is important. Knowing the penicillin
MICs for the Central Australian isolates is very
reassuring. Procaine penicillin or amoxycillin
with probenecid are still very adequate to treat
the recurrent gonococcal conjunctivitis being
transmitted.  The knowledge that in general
penicillinase producing N.gonorrhoeae has not
emerged in Central Australia and the NT is also
reassuring.  The isolates fall within the fully or
less sensitive range (see Table) and will respond
to standard treatment.2  It is prudent, however,
to culture and susceptibility test at least
sentinel samples during an outbreak to
monitor MICs.  The question of what place,
if any, pharyngeal carriage has in acting as
a reservoir for transmission, does need to be
considered but the ability to control outbreaks
with penicillin or amoxycillin with probenecid
rather than ceftriaxone would make this appear
less important. A preparedness to investigate
***************
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this in the event of another outbreak should be
considered.
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Table Penicillin MIC and response to
treatment2
• Fully sensitive to
penicillin, MIC ≤ 0.03
mg/L
• Less sensitive to penicillin,
MIC 0.06- 0.5 mg/L
Usually respond
to standard
treatment
Usually respond
to standard
treatment
• Relatively resistant to
penicillin, MIC ≥ 1 mg/L
 
• Penicillinase producing
N. gonorrhoeae (PPNG)
Usually fail to
respond to
penicillin
Usually fail to
respond to
penicillin
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Guidelines for the Control of Gonococcal Conjunctivitis
Background
Gonococcal conjunctivitis is a highly
contagious eye infection caused by Neisseria
gonorrhoeae.  It is a notifiable disease. Cases
are rarely seen in isolation in the Northern
Territory (NT) and follow up and treatment of
contacts is essential.
Case Definition
Clinical features
A clinical illness characterised by intense
inflammation of the conjunctivae, copious
purulent discharge with or without periorbital
oedema.
Case definition
Neisseria gonorrhoeae detected on culture of a
conjunctival specimen.
OR
Positive diagnosis using a molecular technique
such as PCR (or LCR).
OR
Clinically compatible illness and either
• gram negative intracellular diplococci
visible on microscopy of a conjunctival
specimen
 OR
• epidemiologically linked to a laboratory
confirmed case. This includes any other
proven case in a remote Aboriginal
community.
Clinical Picture
Gonococcal conjunctivitis is usually a localised
infection of the conjunctivae, however corneal
ulceration, perforation and blindness can occur
if treatment is not given promptly.  More
disseminated infection including gonococcal
arthritis has been reported in the NT.
Neonatal infection (ophthalmia neonatorum) is
a potentially more serious clinical picture than
gonococcal infection seen in older children and
adults, and the mode of transmission is
different, which means that management is
different.
Mode of Transmission
In children and adults transmission is either
direct from person to person from
contaminated fingers, or indirect transmission
from contaminated fomites, or from flies.
Heavy rains and an increase in fly numbers
may precipitate an outbreak.
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Neonatal infection occurs during passage
through the birth canal.
Incubation
Usually 2 to 7 days, but sometimes can be
longer.
Period of Communicability
May extend for months in untreated people.
Infectivity ceases within hours of appropriate
antibiotic therapy.  Patients should be
isolated/excluded from school for 24 hours
after treatment.
Diagnosis
Swabs should be taken from all patients with a
discharging eye for microscopy, culture and
sensitivity.
• Wet the swab with sterile normal saline
and swab the eye.
• Roll the swab on a slide and let the slide
air dry.
• Place the swab in Stuart’s transport
medium.
• Do not refrigerate.
• If there is a delay in receiving the
specimen in the laboratory, culture may
fail to grow Neisseria gonorrhoeae,
however gram negative intracellular
diplococci will be visible on microscopy,
and is diagnostic.
Management of Cases
• Collect a swab as above.
• Irrigate the eyes with saline solution to
remove the discharge.
• If possible check visual acuity, and
check cornea for ulceration. If abnormal
refer to local doctor for management.
• Treat with single dose antibiotics (see
below).
• Encourage frequent washing of face and
hands with warm water and soap.
• Warn families to represent if there is
persisting eye infection, fevers or other
symptoms such as arthritis.
• Exclude from school or child care for 24
hours after treatment.
• Report to the Centre for Disease Control
(CDC).
• Treat contacts (see below).
• If a neonatal infection, do a full STD
screen on the mother and then treat.
Treatment
Standard
Neonates: < 1 month (ophthalmia neonatorum)
⇒ Admit to hospital urgently for intra-
venous antibiotics.
Children and adults:
⇒ Procaine penicillin intramuscularly (IM)
as a single dose
50,000 units = 50 mg/kg (to a maximum
of 1,500,000 units = 1.5g)
OR
⇒ Amoxycillin plus probenecid as a single
dose
Weight Amoxycillin Probenecid
3kg to < 6kg 500 mg nil
6kg to < 10kg 1g nil
10kg to <15kg 1.5g 250mg
15kg to <20kg 2g 500mg
20kg or over 3g 1g
Alternative
For cases who are allergic to penicillin, or
where the standard treatment has failed, or if
infection is known to be due to penicillinase
producing Neisseria gonorrhoeae (PPNG)
alternative treatment should be used.  Failed
treatment is defined as no substantial decrease
in discharge, conjunctival injection or peri-
orbital oedema within 24 hours of treatment.
Additionally, if pharyngeal swabs have been
taken and are positive, alternative treatment
should be given.  In an outbreak situation,
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pharyngeal swabs are not routinely recommended
unless symptomatic.
The above cases should be treated with
ceftriaxone:
⇒ Weight ≤ 25 kg: 125 mg dissolved in
1% lignocaine hydrochloride, as a
single intramuscular dose.
⇒ Weight > 25 kg: 250 mg dissolved in
1% lignocaine hydrochloride, as a
single intramuscular dose.
Note: Infants below 6 weeks of age should
not be given ceftriaxone. Refer to
hospital.
Management of Contacts
• Treat all household contacts of a case
with a single does of the standard
treatment of procaine penicillin or
amoxycillin with probenecid (or
alternative treatment as above, if
allergic to penicillin).
• For those with symptoms/signs follow
the steps taken for management of
cases.
• If the case attends a child care or school,
then those in the same classroom need
treatment.
• Encourage good personal hygiene and
regular washing of face and hands with
water and soap.
Meningococcal disease - 2 NT cases in August 1997 - The view from CDC
Vicki Krause1, Kerry-Ann O’Grady1,2, Jan Bullen3,
1CDC, Darwin, 2NCEPH, MAE Program, ANU, Canberra, 3CDC, Katherine
Case 1
On 1 August 1997, the Friday afternoon of the
start of a three day weekend (NT Picnic Day
Monday 4 August) a case of suspected
meningococcal disease was notified to CDC
Katherine by an experienced, long serving,
local GP.
The patient
A 4 year old female vomited the previous day
once at pre-school and was described by her
mother as being “a bit flat”. The child
complained of a sore elbow, shoulder and left
leg but no headache.  She had a fever overnight
and vomited 3-4 times. The morning of
admission, 1 August, she complained of feeling
“dizzy” and her head “hurting”.  During the
course of the morning she developed a purple
rash on her legs and became comatose during
the short drive to the hospital.. Over the next 3
hours while being resuscitated by Emergency
Department staff the rash spread to cover her
trunk, arms and face but became more pink and
less typically purpuric There was no neck
stiffness and negative Kernig’s signs. She
received a stat dose of penicillin and IV
ceftriaxone  She was admitted to hospital under
her local GP and placed in respiratory
isolation.  Her past history revealed that she
was fully immunised including Hib.  The
clinical picture was very suggestive of
meningococcal disease. One reortedly
inadequate blood culture was obtained prior to
antibiotics. A skin lesion aspirate was cultured
post antibiotic.  No lumbar puncture was
attempted as within hours the patients was
showing signs of improvement.  Blood and skin
lesion cultures showed no growth and urine
antigen tests were negative. Of interest, no
nasopharyngeal swab was done. The patient
made a full recovery within a week. No serum
was available to send for further
meningococcal serology investigation.
The public health response
The NT CDC definition of a contact for
invasive meningococcal or Haemophilus
influenzae disease is:
1. Any person who has spent 4 hours or more
a day for 5 consecutive days or more than
24 hours with the index case in the week
prior to the onset of illness.
2. Any person who has significant contact
with the nasopharyngeal secretions of the
index case during the previous week.
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The current NH&MRC Guidelines case
definition of meningococcal meningitis
requires laboratory confirmation. In a small
town with a public health minded GP, the local
Disease Control Unit was promptly notified
even before the possibility of laboratory
confirmation.  The case was convincing as a
highly probable meningococcal meningitis.
The child had close contacts with children in a
pre-school setting, neighbourhood playmates
and a long weekend was approaching with
children likely to disperse and a decision was
needed.  Initially a list of contacts was drawn
up.  At 24 hours with no growth from blood
cultures or skin and after consultation with the
CDC Darwin and RDH Infectious Diseases
Specialist it was decided to inform the contacts
about meningococcal disease, give out an
information pamphlet and dispense rifampicin
prophylaxis to 22 children and 7 adults and
ceftriaxone to a pregnant contact.  A
newspaper article on meningococcal disease
appeared in the local paper the following week.
At six weeks post this probable meningococcal
case there have been no secondary cases.
Case 2
On 12 August 1997 at 1 pm the CDC Darwin
was notified of a suspected case of
meningococcal disease by the public health
conscious Emergency Department at Royal
Darwin Hospital.
The patient
A 14 year old male boarder student at a local
Darwin high school became unwell on the
evening of 11 August with fever, vomiting,
diarrhoea and a headache.  He had first
complained of headache at 3 pm that afternoon.
He was taken to a private hospital at 8 pm with
a provisional diagnosis of viral illness and
dehydration.  IV fluids and paracetamol were
given and he was sent home.  He again
presented at 9 am the following morning, 12
August, with persistent fever 38°C, vomiting,
photophobia, drowsiness, headache,
generalised aches and pains and diarrhoea.  A
widespread purpuric rash had developed.
There was no neck stiffness and a Kernig’s
sign was negative. A provisional diagnosis of
meningococcal meningitis was made and IM
ceftriaxone given.  He was transferred to the
Royal Darwin Hospital, admitted and placed in
respiratory isolation and commenced on IV
ceftriaxone and penicillin.  The patient had no
significant medical history and no recent
illnesses other than a “blocked nose”.  He had
not been out of Darwin since the school
holidays 5 weeks previously and had only left
the school on weekends to stay with a friend’s
family.  One member of that family had been ill
with fever and mild abdominal cramping the
preceding week which was diagnosed as a viral
illness by the family GP.  Blood cultures and a
small amount of CSF were obtained after
antibiotic treatment and vesicular fluid from a
skin lesion associated with the rash was
cultured.  The patient did not have a
nasopharyngeal swab. CSF and blood cultures
were negative, however fluid from the skin
lesion grew Neisseria meningitidis at 24 hours.
The isolate was sent to the National Neisseria
Network and serogroup identification is still
pending.  The isolate was fully sensitive to
penicillin.  The patient made a full recovery
within a week.
The public health response
By 8 pm on the evening of 12 August before
the isolation of N.meningitidis, 111 people had
been identified who had met the above NT
CDC definition of a contact for prophylactic
rifampicin. These included dormitory residents,
house parents, a football team who had shared
water bottles, the family the patient boarded
with on the weekend and his classmates.
Additionally 4 people insisted they be
considered as contacts despite minimal contact
and assurance that their level of risk was
minimal.  20 contacts considered most at risk
according to the degree of contact were
medicated on the evening of admission.  These
consisted of the patient’s room mates, the
family he stayed with on the weekend and
houseparents and others who had come in
contact with vomitus etc on the evening of 11
August.  A decision was made to wait until
laboratory confirmation was obtained before
rifampicin was given to the remaining contacts.
Confirmation was received at 10 am 13
August. By 4 pm that day, all remaining
contacts had received the first dose of
rifampicin.  A letter from CDC, an information
pamphlet on meningococcal disease and
rifampicin were provided to all contacts and
their families.  There were numerous calls to
CDC and the school nurse from concerned
parents, friends and school staff.  Information
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sessions were held with staff and students at
the school.  A notice was prepared for the
school’s newsletter at the principal’s request
and a press release prepared for the local
media.  Staff involved in the public health
response included the school nurse, 3
pharmacists and 2 CDC staff.  It had taken at
least 70 personnel hours in contact tracing,
education and medication distribution.  The
cost of rifampicin was approximately $3000.
Discussion
These two cases have raised a few issues in
regards to the NH&MRC October 1996
endorsed Guildelines for the Control of
Meningococcal Disease in Australia1, which
are generally very thorough and useful.  The
issues are also timely as the NT Guidelines for
Meningococcal Meningitis/Septicaemia Prophylaxis
are currently being revised.
The first issue is the definition of disease.
Both the NH&MRC case definition and the NT
CDC current definition of meningococcal
disease require laboratory confirmation, ie
isolation of N.meningitidis from a normally
sterile site or detection of meningococcal
antigen in joints, blood or CSF or detection of
gram negative intracellular diplococci in blood
or CSF.  There is no provision for probable
cases. The USA CDC case classification2
allows for a probable case where there is a
positive antigen test in CSF or clinical purpura
fulminans in the absence of positive blood
cultures. The UK Meningococcal Working
Group3 define meningococcal disease as
confirmed, probable or possible.  Confirmed
disease includes microbiological confirmation
and probable cases include a clinical diagnosis
of meningococcal meningitis/septicaemia
without microbiological confirmation where
the Disease Control or Public Health Specialist
in consultation with the clinician managing the
case consider that meningococcal disease is the
likeliest diagnosis.  Confirmed and probable cases
require intervention.  The first case presented meets
these definitions of probable meningococcal
meningitis deserving intervention.  The current
NH&MRC Guidelines do not address a
probable category and therefore no public
health intervention is considered. As earlier
and appropriate patient treatment occurs
laboratory confirmation will be obtained less
frequently.
When meningococcal infection is
suspected, particularly where actual or
insipient shock is evident, immediate
imperic therapy in the abscence of
formal diagnosis is indicated.
Treatment should commence
immediately before transfer to hospital
and not be withheld until
N.meningitidis or another organism has
been identified. This is particularly
important with patients with a
haemorrhagic rash.1
There is a need to at least address what to do
when there is no microbiologic confirmation.
The second issue follows from the first.
Even when a probable case category exists
emphasis should still be placed on
obtaining laboratory evidence.  A full range
of specimens (beyond CSF) for testing
should be taken on every case suspected of
meningococcal disease. The traditional
lumbar puncture to obtain CSF is now
frequently deferred until therapy and
supportive measures have been established and
investigations such as a CT have ruled out
increased intracranial pressure.  Alternative
diagnostic specimens therefore are important.
Collection of blood for culture should be
attempted prior to antibiotics (but not delay
antibiotics) and a throat/nasalpharyngeal
swab should always be obtainable.
Unfortunately on page 1 of the NH&MRC
Guidelines, the fifth point reads “There is no
indication for use of throat/nasalpharyngeal
swab in routine management”.  This actually
should go on to read “in routine contacts” and
is misleading.  On page 10, under “Patient
Management”, subsection, “Diagnostic
Studies” the correct advice is given: “All
patients with suspected meningococcal
infection should have blood and a
throat/nasalpharyngeal swab collected as soon
as possible for culture”. The public health
physician’s role on notification of a case is to
recommend to the managing clinician that a
throat swab be taken if antibiotics were given
to the patient before referral to hospital or if
the organism has not been cultured from a
normally sterile site.  Additionally, a collection
of fluid from skin lesions for meningococcal
culture or presence of gram positive diplococci
should be encouraged. Routine microbiological
surveillance for meningococcal infections
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should include the serogroup and antibiotics
sensitivity of all isolates of N.meningitidis and
isolates should be referred to the National
Neisseria Network (NNN) to confirm
identification, antibiotic sensitivities and
provide further characterisation.  As the public
health response to an outbreak is also
influenced by these findings some timeliness in
reporting is expected. This becomes more of an
issue when there is more than one case.
Participation in projects to explore the utility of
other means of enhancing laboratory diagnosis
eg newer or novel tests should be encouraged.
A third issue is the definition of a contact.  The
NT definition has historically been the same
for meningococcal and Haemophilus influenzae
disease and differs somewhat from the 8 point
NH&MRC definition on page 33.  Possibly
they complement each other.
A final issue which has come up in revising the
NT Guidelines both for meningococcal and for
gonococcal conjunctivitis contacts is the dosing
for ceftriaxone, should this alternative to
rifampicin be required. The dosage of 5 mg/kg
as per the Antibiotic Guidelines4 is impractical
to measure in low doses and the NH&MRC
Guidelines are somewhat confusing and based
on age rather than weight.
The simplest rational method would appear to
be to give 250 mg dissolved in 1% lignocaine
hydrochloride, as a single intramuscular (IM)
dose for those over 25 kg and 125 mg dissolved
in 1% lignocaine hydrochloride, as a single IM
dose in those 25 kg or under, recognising that it
is not to be used in infants below 6 weeks of
age.
The revised NT Guidelines for Meningococcal
Meningitis/Septicaemia Prophylaxis will be
published in the next Bulletin.
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El Nino - ? drier wet season, but still expect melioidosis
and other “tropical” infections
Bart Currie, Royal Darwin Hospital and Menzies School of Health Research
Melioidosis (disease from infection with
Burkholderia pseudomallei) predominantly
occurs during the wet season.  However the
amount of rainfall does not definitively predict
the number of melioidosis cases.  With the
record wet in 1996/97, between November and
April, there were 24 Top End cases of
melioidosis with 5 deaths plus an additional
case of non fatal relapsed melioidosis
associated with non-adherence to eradication
therapy.  From May to August 1997 there have
been 2 new cases and 2 relapsed cases, all non
fatal.
Over the last eight years the average number of
cases and deaths per year was 23 and 5, with
181 cases and 40 deaths overall.  Even with the
predicted drier wet season ahead, melioidosis is
likely to still be the commonest cause of fatal
community-acquired septicaemic pneumonia at
Royal Darwin, Gove and Katherine Hospitals.
It will once again be important for staff new to
our Top End hospitals and to urban and rural
health centres in the Top End to be made aware
of melioidosis and other infectious diseases
uncommonly seen in southern Australia.
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Other details on melioidosis
1. Apart from pneumonia, other presentations
of melioidosis include skin abscesses or
ulcers, abscesses in internal organs such as
prostate, spleen and liver, fulminant
septicaemia with multi-organ abscesses and
unusual neurological illnesses (such as
brainstem encephalitis). Individuals without
symptoms or a known history of disease
have also been found to be serologically
positive.
2. While melioidosis can occur in children and
healthy adults, almost 40% of cases are
diabetic and 40% are excessive alcohol
consumers.  Excessive kava drinking also
appears to be associated with melioidosis.
3. The likelihood of diagnosis is increased by
using selective culture media (modified
Ashdown’s broth), frequent sampling
(sputum, throat, rectal and ulcer swabs) and
collection of blood cultures.  Clinicians
should liaise with laboratory staff to ensure
selective media are available, including for
remote communities.
4. Mortality is decreased by early diagnosis
and appropriate antibiotic therapy.
5. Follow up of cases and adherence to
eradication therapy (usually at least three
months of antibiotics after discharge) is
critical to prevent relapse, which can be
fatal.
6. The Top End empirical treatment protocol
for adult community-acquired pneumonia is
devised to cover both melioidosis in
patients with risk factors, as well as other
important pathogens (Table over).
7. Once melioidosis is confirmed the treatment
recommended is:
Initial INTENSIVE therapy for usually 14
days or more of:
-  intravenous high dose ceftazidime
plus either
-  high dose cotrimoxazole
or
-  high dose doxycycline.
This is followed by ERADICATION
therapy for at least three months of:
- oral monotherapy with either high dose
cotimoxazole or doxycycline.
Examples of other infections of particular local
interest include:
i. Scrub typhus from Litchfield Park - the
only known NT focus.
ii. Murray Valley Encephalitis - no case
since 1993, but a nasty disease with
mortality over 25% in those with
encephalitis - will periodically “break-out”
of its endemic northern Western Australia
- Top End NT mosquito-animal cycles to
cause human cases sporadically or in
clusters or a larger epidemic.  Most
infections are actually subclinical.
iii. Barmah Forest Virus - although increasing
as a cause of fever, rash and polyarthritis
in southern Australia, the first true
epidemic was described from Nhulunbuy
in the 1991/92 monsoon.
iv. Cryptococcal meningitis - should be
considered in anyone with persistent
severe headache, especially in remote
Aboriginal communities. The “tropical”
variant, Cryptococcus neoformans var
gattii, occurs in overtly immunocompetent
people and may also present as a lung
mass(es) on CXR.  The connection with
eucalypts remains to be sorted out in the
NT.
v. Crusted (Norwegian) scabies - often the
source of community or hospital outbreaks
of scabies due to the thousands, even
millions, of mites in the hyperkeratotic
skin plaques.  Requires intensive therapy
and infection control measures.
vi. Community-acquired (“tropical”)
Acinetobacter baumannii pneumonia -
unusual (1-2 cases/year Top End), usually wet
season and fatal and almost always in
alcoholics. Presents as fulminant
lobar/total lung pneumonia.
Because of melioidosis and Acinetobacter
pneumonia, while recognising that
Streptococcus pneumoniae is the commonest
overall cause of pneumonia (and second to
melioidosis as a documented cause of death in
the Top End), the following is the Top End
protocol for initial therapy of adult community-
acquired pneumonia.  With the wet season
approaching please make new staff aware of
this.
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Table Initial therapy of adult community-acquired pneumonia in the Top End1
Mild pneumonia Moderate pneumonia Severe pneumonia
No risk factors2 present Penicillin Penicillin Ceftriaxone
Risk factors2 present Penicillin Ceftriaxone plus
gentamicin
Ceftriaxone or ceftazidime
plus gentamicin
1. For ‘atypical pneumonia’ consider adding erythromycin.
2. Risk factors include: alcohol, diabetes, chronic lung disease, chronic renal failure and steroid therapy.
Guidelines for Community Control of Scabies and Skin Sores
Background
Scabies and skin sores are one of the
commonest problems seen in health centres.
Scabies sores often become infected.  Severe
scabies contributes to malnutrition in children,
because their body needs extra energy to heal
the skin sores.
The high rates of streptococcal skin sores cause
Acute Post Streptococcal Glomerulonephritis
(APSGN), which may be severe with swelling
of the face, high blood pressure and dark
(blood stained) urine.  It can also be very mild
with haematuria (blood) found just on urine
test.  Research in the Northern Territory (NT)
suggests that frequent mild episodes of APSGN
in children are contributing to high rates of
kidney disease in adults. High rates of skin
infection allow the streptococcus to remain
circulating in communities, leading to the
extremely high rates of rheumatic fever and
rheumatic heart disease seen in the NT.
Treating individuals, or even whole families
for scabies will not be successful in reducing
community rates.  Up to 50% of children are
infected in some communities and people get
reinfected very quickly. This causes continual
frustration for community members and health
staff.
Community Scabies Program
A successful community program to control
scabies has occurred in one Top End
community over the past two years.1  This was
based on a successful program devised to
control scabies among Kuna Indians in
Panama.2  A simple form of those programs
would help to reduce and control scabies in
other communities.
There are three requirements:
1. Community support and education.
2. Single community scabies treatment of
all residents at the same time.
3. Maintenance program involving:
• simple screen of all children less
than 15 years of age, three times per
year to check skin for scabies and
skin sores
• ongoing community education and
evaluation of the program
1. Community support and education
Treating all community members at the same
time regardless of whether an individual has
scabies is the only effective method to
significantly reduce the high prevalence rate.
Most communities will need extra staff to
assist with community screening and treatment.
Although this involves a large commitment of
time and effort by local health staff and the
community, it will show results within a short
time and significantly reduce the clinic work
following the scabies program.
Health staff education
Health staff should arrange education sessions
for themselves:
• to ensure everyone understands the issues
• to ensure staff are confident in diagnosing
scabies
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• to obtain appropriate educational materials
for community education
• to organise the community screening and
treatment program
Community support
Discuss issues with key leaders and decision
makers to enable them to recognise:
• the serious short and long term outcomes
of continuing high rates of scabies
• the high rate of success with full
community involvement
Ask council members, community elders,
teachers, Health Boards, Arts Centres, CDEP
workers, Woman’s Centre members, outstation
resource centres and other appropriate people
to take the message to their families.
Community education
Education is essential to promote full
participation. AHW’s and other local trusted
health staff are the best people to provide this
education. Arrange school and community
education sessions and include information on
personal health practices, such as regular hand
and face washing, daily bathing, toothbrushing
and washing of clothes and linen.
Resources
The issue of resources is currently being
looked at by CDC, Rural Services, Health
Promotion and Environmental Health.  The
plan is to develop educational materials such as
posters, videos, booklets and pamphlets to
assist community staff in providing this
program.  Funding will also need to be
established to cover costs such as the scabies
treatment, publicity materials and transport of
extra staff.
2. Initial screen and community
treatment
Arrange community screening and treatment.
The time taken will depend upon the size of the
community and number of outstations.
Allocate at least one week.
There are two main reasons for screening:
1. To establish the baseline prevalence rate
for your community which provides a
comparison at follow-up screening.
2. To determine which individuals have
infected sores and need antibiotics.
Who to screen
• Children are the main group that must be
seen, as they have the highest rates of
infected scabies.
• It is desirable but not essential to screen
adults, but if adults are not screened it is
important to ensure that all adults as well
as children are treated.
How to screen
• Organise resources prior to screening (eg
staff, scabicide).
• Organise all equipment prior to screening
day.
• Organise appropriate screening area (eg
school, clinic, Woman’s Centre).
Screening
Scabies:
• Look for small papules and scratch marks
around web spaces between fingers and
toes and around wrists. Children often
have scabies papules on elbows, armpits
and trunk. Babies can have widespread
scabies including the head, and pustules
on their palms and feet. Adults mostly
have lesions in web spaces. Scabies is
almost always itchy. Document if scabies
present with a simple Yes/No and record
presence of moderate to severe scabies, as
these people need repeat treatment.
Skin sores:
• Document presence of sores (Yes/No)
only for infected sores. Do not include
non-infected cuts, scratches or insect bites.
Sores will be moist or have pus, or have a
yellow/brown crust. Treat all people with
sores with a single intramuscular (IM)
dose of benzathine penicillin (or
erythromycin for 10 days if allergic to
penicillin).
• Permethrin can be applied at the time
antibiotic treatment is given. There is no
need to wait for healing, as permethrin has
very low skin irritation.
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Age groups:
• Young children: check all of skin,
including scalp.
• School children: check hands, arms, legs,
feet and waist.  Only check rest of skin if
scabies or sores noted, or if itching is
present on other parts of the body.
• Adults: check hands, arms and feet, unless
scabies or sores found.
• Document and offer treatment for other
skin problems (eg ringworm).
Treatment
• Give out scabies treatment to the whole
community at the same time.
• Health staff should visit households to
demonstrate the correct way to use the
cream by treating some young children.
• Use 5% permethrin cream for everyone
older than 2 months.  Permethrin is
recommended because it is simple to use
and has low rates of skin irritation.  (For
babies under 2 months, see below).
Everyone should treat themselves late in
the afternoon or evening by applying
permethrin cream from head to toe,
ensuring the whole body is covered,
avoiding eyes and mouth. Previously we
only treated young children head to toe,
but in endemic areas many older children
and adults have scabies on their head and
neck.  The cream should be left on
overnight (8-12 hours) and washed off in
the morning.
• Repeat scabies treatment in two weeks for
all people with moderate to severe scabies.
This includes infants with pustules on
hands and feet, and other people with
multiple scabies lesions.
• Babies younger than 2 months of age can
be treated with sulphur 5% cream daily for
2 to 3 days or crotamiton 10% cream
(Eurax) daily for 3 to 5 days, depending
on how quickly they respond.  Wash off
and reapply the cream once each day. Do
not use permethrin as it may be absorbed
and cause problems.
People with crusted scabies (Norwegian
scabies) are very infectious as they have
thousands of scabies mites on their skin.  These
people usually need initial hospital treatment
and their houses need special cleaning (see
Crusted Scabies protocol).
Reducing the high rate of scabies depends upon
treating all possible human hosts at the same
time.  Cleaning of sheets, blankets and clothes
and treatment of mangy dogs is not essential
for success.  However, community members
may wish to encourage these activities as part
of personal health practices and to improve dog
health.
3. Maintenance Program
It is important to continue screening children’s
skin regularly over the long term, until endemic
scabies has disappeared from Aboriginal
communities. If health staff don’t continue four
monthly skin checks, the prevalence of scabies
will slowly increase until it returns to pre-
treatment levels.
Screening
• screen all children one month after
community treatment
• then screen all children three times per
year (this can be combined with regular
de-worming in the Top End)
• treat any skin sores with penicillin (or
erythromycin if allergic) and
• treat any child with scabies AND all
family members living with them
The clinic and school could decide on three
screening dates at the start of each school year.
Ideally, this screening could be done on the
same three dates within a region eg 1st week in
February, June and October.
Individual clinics should decide how they will
combine maintenance skin checks with the
school screening program.
Community education
In order to maintain community interest:
• evaluate the success of your program and
feedback the information on a regular
basis to community decision makers such
as Councils, Woman’s Centres,
community elders and teachers
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• encourage community residents to
present early for treatment of scabies or
skin infections
• encourage community residents to refer
visitors to health centre for early
treatment continue positive promotion of
the benefits of personal health practices;
and encourage community councils to
lobby for improved “health hardware” ie
appropriate housing, showers, toilets,
washing machines
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Editorial
Following discussions at a recent Menzies
School of Health Research streptococcal
symposium attended by international experts,
the recommended treatment of scabies for
individuals has been changed. These new
recommendations will appear in the next
edition of the Antibiotic Guidelines, but all
staff should adopt these changes now. The
changes are:
1. Infected scabies: treat with permethrin and
antibiotics at the same time.
Permethrin causes very little irritation on
broken skin, so the 2 day delay is not
required.
2. Treat all adults and children with scabies
from head to toe.
In tropical and endemic areas, scabies
lesions are frequently found on the scalp
and behind ears in adults as well as young
children.
3. Retreat people with moderate to severe
scabies in two weeks.
Treating in one week is too early, as some
eggs may not have hatched and will not be
killed by the permethrin.
Contact CDC, Darwin on 8922 8044 for a copy of
the guidelines including Appendices 1-3.
Non-Communicable Diseases Update: No.3
Message: Cholesterol reduction: base your primary prevention strategy on
overall cardiovascular risk, and emphasise non-drug options first
Tarun Weeramanthri, Community Physician, CDC, Darwin
In the March edition of the Communicable
Diseases Bulletin, the importance of aggressive
drug treatment of hyperlipidaemia in those
known to have cardiovascular disease was
stressed. This article looks at the evidence for
more aggressive primary prevention strategies
(both drug and non-drug) in those
asymptomatic individuals at risk of, but
without currently diagnosed, cardiovascular
disease.
The WOSCOP Study
The results from the West of Scotland
Coronary Prevention Study (WOSCOP) were
reported in late 1995.1 The study was restricted
to middle aged men. 6595 men with no history
of myocardial infarction were randomly
assigned to pravastatin or placebo and followed
up for an average of 4.9 years. There was an
approximate 30% reduction in definite
coronary events and death from coronary heart
disease in the pravastatin group. The reduction
in coronary events was independent of baseline
levels of LDL cholesterol. Overall mortality
was 22% lower in the pravastatin group, but
this was just short of statistical significance
(p=0.051). Strangely, this was not a pure
primary prevention study, since men with
angina (5% of the study population) were not
excluded. The results of this trial are
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supportive of a more aggressive approach to
primary prevention, but it should be
remembered that the study population had a
high average baseline total cholesterol of 7.0
mmol/L and LDL of 5.0 mmol/L. In addition,
no women were included. So the study results
cannot be directly extrapolated to the whole
population.
A subsequent analysis of six trials of primary
prevention, including WOSCOP, has estimated
that one would have to treat 53 patients without
known atherosclerosis with lipid-lowering
drugs for five years to prevent one additional
non-fatal infarction or cardiac death, compared to
only 16 patients with known atherosclerosis.2
In the March edition of the Bulletin, it was
noted that the cost effectiveness of giving lipid-
lowering drugs to those with known coronary
disease had been estimated by the
Scandanavian Simvastatin Survival Study
group to be $A 12,400 per year of life saved,
comparable to bypass grafting for the usual
indications. In those without coronary disease,
the cost per year of life saved is estimated to be
at least four times that amount.3
The Cholesterol Screening Debate
The WOSCOP results, however, have not
settled the issue of who should be screened for
high cholesterol levels.4 For example in the
United States, the American College of
Physicians recommends only limited screening,
primarily for middle-aged men, or those with
two coronary risk factors, whereas the National
Cholesterol Education Program recommends
that all adults over the age of 20 years know
their cholesterol level. The National Heart
Foundation (NHF) of Australia has adopted a
similarly aggressive position.5
Proponents of limited screening point out that
clinical trials have not been done in young
adults and that the number of women included
in trials has been small. They are worried about
the costs of cholesterol-lowering medications
and the possibility of over-prescription driven
by a rising consumer demand. For example, the
NHF of Australia’s ‘Guide to Plasma Lipids
for Doctors’ recommends that drug therapy be
considered in asymptomatic people with a total
cholesterol over 6.5 mmol/L but only if they
have other risk factors and dietary therapy has
not worked after 6-8 weeks. How many people
would that apply to in Australia? Well, the
1989 NHF Risk Factor Prevalence Study found
that, in adults aged 20-69 years, 16% of men
and 14% of women had levels of 6.5 mmol/L
or more.6 Treating large numbers of people
with drugs would be expensive and the
opportunity costs would be large. Any benefits
that could theoretically accrue based on the
trial data would also be lessened in real life, if
the high discontinuation rates (60% after 12
months) seen in one Australian study were to
prevail.7
Proponents of widespread screening point out
that knowledge of cholesterol levels does not
automatically lead to drug therapy and that
measuring one’s cholesterol may reinforce
behavioural change by focusing attention on
diet, smoking and other cardiac risk factors,
although they concede that the magnitude of
any such changes are likely to be modest.8 In
any case, if drug treatment is needed, it can
yield as much benefit as the treatment of mild
and moderate hypertension, and the numbers in
the population needing treatment are similar to
those with hypertension.
Proponents of widespread screening also stress
that the distinction between primary and
secondary prevention is not especially relevant
as those most likely to benefit from primary
prevention are most likely to have advanced
but asymptomatic atherosclerosis at the time
treatment is started. There is a risk in waiting
for symptoms to develop as in approximately
25% of patients with atherosclerosis, sudden
death is the first manifestation.
Assessing overall cardiovascular risk
All in all, the approach to primary prevention
of cardiovascular disease through lipid-
lowering therapy in Australia is changing and
becoming more aggressive. As previously
mentioned, the recently updated NHF
guidelines recommend that all adults,
excluding pregnant females, should have their
total cholesterol, HDL cholesterol and
triglycerides measured, and proposes lower
treatment targets than the PBS guidelines.
The proposal for universal testing irrespective
of predicted risk is contentious, but the
principle of assessment of overall risk prior to
drug prescription is now agreed upon and has
been incorporated into the PBS guidelines first
published in 1994. Paradoxically, in deciding
whether to treat elevated cholesterol levels in
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the asymptomatic individual, the level of
cholesterol is not the only or even the most
important factor. Instead of treating the isolated
cholesterol level, one should base the decision
to treat on an assessment of the overall
cardiovascular risk, taking into account age,
gender, family history and other risk factors
such as diabetes, hypertension and smoking.
There are an increasing number of risk charts
being produced to help practitioners calculate
the overall cardiovascular risk for an
individual. For example the Sheffield risk table
identifies those with a risk of coronary death
over 1.5% per year based on age, gender,
cholesterol concentration and the presence of
hypertension, smoking, diabetes and left
ventricular hypertrophy on ECG.9 However,
there is considerable uncertainty as to how to
integrate such risk tables into routine clinical
practice and how to incorporate other relevant
information such as client preferences, cost of
treatment, years of life gained, and probability
of adverse events.10
In the future, more effective non-drug therapies
are needed that could be applied in population
interventions to reduce hypercholesterolaemia.
Effective population interventions to increase
exercise and activity levels, and to change
national dietary intakes of salt and saturated
fats must be developed. There are also
emerging options such as using plant sterols,
that are known to inhibit cholesterol
absorption, dissolved in margarine.11
We await further trials of primary prevention
of coronary heart disease in groups other than
middle-aged men. Meanwhile there is a need to
focus on risk factor modification, and
development of expertise in tailoring dietary
and activity advice to an individual’s personal
circumstances and in offering options such as
smoking cessation. The preferences and values
of the patient must be taken into account
whenever lipid-lowering therapy is considered.
Any decision to start and monitor a medication,
that may need to be continued over a lifetime,
needs to be made jointly.
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Acute respiratory illness in 2 Darwin schools
Kerry-Ann O’Grady1,2 and Fay Johnston1
1CDC, Darwin, 2NCEPH, MAE Program, ANU, Canberra
Towards the end of May 1997, Darwin Centre
for Disease Control (CDC) received reports of
an illness characterised by a sore throat, runny
nose, fever, lethargy, cough and occasionally
vomiting and diarrhoea, affecting large
numbers of staff and students in Darwin
schools. An investigation was undertaken of
staff with the objectives of identifying the
illness, establishing if it was an influenza
outbreak, documenting the impact on the two
schools and determining whether any public
health action could be taken.
A case was defined as a member of staff who had
experienced a sore throat plus 2 or more of the
following symptoms any time since 1 May 1997:
fever, runny nose, cough, lethargy, generalised
aches and pains, vomiting, diarrhoea, nausea, chills
or rigors and weakness. People meeting the case
definition had blood taken for influenza A and B,
adenovirus, mycoplasma, respiratory syncytial
virus (RSV) and parainfluenza. If acutely unwell, a
throat swab was also collected for influenza
cultures.
School A (n=26) had 84% and School B (n=47)
had 91% of staff participate in the investigation.
The remaining staff were on leave at the time.
School A had 14 staff (63%) and School B had 26
staff (60%) who met the case definition. In addition
to the sore throat, a cough, runny nose and
weakness were reported most frequently. Fever
was reported by 45% of all staff. The median
length of illness was 3 days (range: 2-42 days).
School A had 43% and School B had 50% of
staff off work for a median of 2 days (range: 1-
12 days). There was a total of 50 days of lost
productivity in staff alone. Student absenteeism
in one school ranged from 15-75% throughout
May.  Fifty three percent of all staff had family
members who had illnesses similar to their own
in the same time period.
Blood was collected from 11 staff members in
School A and 18 in School B. No throat swabs
were obtained as no staff were acutely ill at the
time of the investigation. No staff had viral
titres considered diagnostic for acute infection,
however levels suggestive of past or early
infection were found in 80% of ill staff, with
RSV and parainfluenza 3 being the most
common.
Unfortunately a specific organism was not
identified, but we are reasonably certain this illness
was not Influenza A or B. The impact on the
schools, however, was significant. There had been
considerable disruption to school routine and class
progress. In addition, the attack rates in staff’s
families suggest the illness may have been
widespread in the community.
While results were inconclusive, benefits have
arisen from this investigation. Firstly, it was an
avenue for promoting CDC’s role in outbreak
investigations, the potential public health
importance of acute respiratory illness (ARI)
outbreaks and the reasons for early notification.
School staff are in a position to alert public health
authorities if an unusual health event occurs so that,
when appropriate, immunisations and
environmental investigations can be implemented
and, where possible, the public can be informed
and reassured.
Secondly, public education regarding the
prevention and control of communicable diseases
was delivered. Inservices were given to provide
feedback and answer questions. There was a
particular interest in the modes of transmission of
viral illnesses and in how they could be controlled
in the school setting. The sessions provided a
forum for discussing the transmission of acute
respiratory illness (ARI), pushing the general
immunisation message, emphasising the benefits of
healthy diets, exercise, not smoking, handwashing,
covering one’s mouth when coughing or sneezing,
staying home when unwell, and for encouraging
staff to alert CDC early whenever they are
concerned about illness in their environment.
Active campaigns would be beneficial in these
environments at the start of each year. While ARIs
will not be eradicated, raising awareness of the
public health implications of disease may facilitate
early public health initiatives (eg immunisation
campaigns) and encourage institutions to consider
strategies for reducing the impact of these diseases
in their environments. These strategies could
include the promotion of handwashing and
encouraging staff  to stay at home when ill.
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Hepatitis C Community Awareness Campaign
Naomi Oliver, AIDS/STD Unit, CDC, Darwin
It is thought that hepatitis C is greatly
underdiagnosed and that the current hepatitis C
notifications are only the tip of the iceberg.  Dr.
Alex Wodak (Director, Alcohol and Drug
Services, St. Vincent’s Hospital, Sydney)
estimates that between 50,000 to 200,000
people Australia wide are infected with the
virus.  Unlike hepatitis B, only 20% of people,
once infected, will eliminate this virus from
their body.  Currently there is no vaccine or
cure and treatment is only effective and
available for a small percentage of people.
Since testing began in 1990 to 26 August 1997,
there have been 1,352 notification in the NT -
56 in the last two months.
The Hepatitis C Network NT report that many
people who are hepatitis C positive do feel
unsupported by the community and medical
organisations. Fear of discrimination by
employers, insurance companies and others
who are ignorant of the facts, is often a
complaint. There are still a lot of unanswered
questions.  The results of a small survey show
that whilst most people have heard about
hepatitis C, there is little understanding within
the community of the virus, its transmission
modes and its consequences.
In January of this year staff of the AIDS/STD
Unit, Alcohol and Other Drugs and other key
organisations decided to conduct a community
awareness campaign for the purposes of
increasing knowledge of hepatitis C and
providing the community with an avenue
through which they could access further
information. Staff working on this project were
mindful of the possible stigma which can be
associated with hepatitis C and carefully
planned materials and media information.
The focus of the campaign was the
implementation of a hepatitis help line using a
1 800 number that is available Territory wide.
During the first month, when the majority of
the advertising occurred, the line was staffed
from 9am - 5.30pm.  Calls were monitored and
approximately 50 calls came in within the first
9 days.  As was expected, calls have tailed off,
and the line is now staffed for two hours per
day on an ongoing basis.  Members of the
public can ring between 9am - 11am or
alternatively leave a message for their call to be
returned.
Levels of transmission are the highest amongst
people who have injected drugs.  Accurate
figures are difficult to ascertain, but it is
estimated that after two years of injecting
drugs, approximately 66% of people will be
Hepatitis C positive, and 100% after 8 years of
injecting drugs.  Dr. Wodak estimates that
there is one new hepatitis C infection per hour
in Australia amongst people who inject drugs
(8,000-10,000 estimated new infections per
year in injecting drug users).
Other high risk groups include young people in
general, and prisoners, both possibly reflecting
use and experimentation with injecting drugs.
In the southern states a high proportion of
prisoners are convicted for drug related crimes.
The percentage in the NT is smaller, but the
overall rate of hepatitis C in NT prisons is still
about 9 times higher than in the general
community. For these reasons part of the
campaign focuses on the three identified
groups.  Specifically targeted messages have
been placed in venues which these risk groups
are likely to frequent, and face to face
education is occurring via different agencies
and Territory Health Services (THS).
The campaign was launched on Wednesday 6
August by The Minister for Health, Family and
Children’s Services, The Hon Denis Burke.
The event attracted considerable interest from
the media and was attended by approximately
40 people from a number of non government
organisations as well as THS personnel.
Future work will focus on education and
prevention amongst the target groups specified
above.
The help line number is 1 800 353 755
Immunise Australia
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Chris Nagy, CDC, Darwin
The Federal Government’s Immunise Australia
campaign was launched on 28 July 1997.  The
campaign aim is to increase the level of age
appropriate immunisation within the
community by raising awareness to the benefits
of immunisation and to provide Australians
with the information they need to make
informed immunisation decisions.  In addition,
three National Immunisation Days have been
designated to offer the public immunisation at
locations and times which may be more
accessible.  These dates are three Saturdays, 2
August, 4 October and 6 December 1997.
Territory Health Services has participated so
far in the campaign by holding immunisation
clinics at Casuarina Community Care Centre,
Katherine Health Centre and the Palmerston
Shopping Centre on the 2 August. The clinics
were supported by national and local
advertising and shopping centre displays in the
week leading up to the immunisation day.
Attendance and public response to the clinics
was pleasing, with 60 adults and children being
immunised and many more requesting
information. Immunisation rates in the
Northern Territory are lowest in the urban and
urban satellite areas, hence this is where the
campaign is being focussed. Providing
accessible Saturday clinics should work to
improve coverage in the target groups e.g. the
children of working parents or parents with
transport difficulties and for adults. Regular
weekday baby clinics are provided at the
Casuarina Community Care Centre in the
northern suburbs, however, Saturday clinics are
not usually available. Provision of a Saturday
immunisation clinic at Katherine Health Centre
was very successful and well attended. At
Palmerston, a vacant shop within the shopping
centre was transformed into a clinic and it was
by far the busiest clinic on the day. Users
described its convenient location as its main
advantage. A full report is available from CDC
on 8922 8487.
Increasing public awareness to immunisation
through advertising and taking immunisation to
the public in their preferred locations and time
should ultimately fulfil the goals of this
campaign.  A full evaluation of the Program is
being undertaken by the Commonwealth.
Immunisation clinics are planned for 4 October
at Gove Infant and Maternal Health Centre,
Palmerston Shopping Centre, Tennant Creek
and Alice Springs shopping areas. The final
National Immunisation Day locations are yet to
be finalised.
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NT NOTIFICATIONS OF DISEASES BY DISTRICTS
1 APRIL TO 30 JUNE 1997 AND 1996
DISEASES ALICE
SPRINGS
BARKLY DARWIN EAST
ARNHEM
KATHERINE TOTAL
   '97    '96    '97    '96    '97    '96    '97    '96    '97    '96     '97      '96
Acute Rheumatic Fever       2       1       0       0       1       8       0       1       0       2        3       12
Adverse Vaccine React.       1       2       0       0       2       3       1       1       2       0        6         5
Arbovirus infections
 Barmah Forest Virus       4       1       5       0       7       4       0       2       4       0      20         7
 Kunjin Virus       0       0       1       0       0       0       0       0       0       0        1         0
 Dengue       0       0       0       0       0       1       0       0       0       0        0         1
 Ross River Virus     35       0     10       4     40     17       1       1       6       2      92       24
Campylobacter     40       3       1       2     15     51       2       0       4       9      62       65
Chlamydia     62     48     11       5     67     53     21     22       8     35    169     163
Cong.Syphilis       0       0       0       0       0       0       0       0       0       1        0         1
Donovanosis       2       3       0       1       0       0       0       1       0       0        2        5
Glomerulonephritis       0       0       0       0       2       0       0       0       0       0        2        0
Gonococcal Disease   125     72     13       7   141     29     27     23     34     40    340     171
Gonococcal Conjunct.     93       0       2       0       0       0       0       1       0       0      95         1
Haemophilus Inf type b       1       0       0       0       0       0       0       0       0       0        1         0
Hepatitis A     17       3       3       1       8     10       0       2     13       6      41       22
Hepatitis B       1       2       4       0       2       0       0       0       4       1      11         3
Hepatitis C (prevalence)       8       9       0       1     65     62       0       0       2       2      75       74
Hepatitis D       1       0       0       0       0       0       0       0       0       0        1         0
HIV infections       0       0       0       0       2       2       0       0       0       0        2         2
HTLV-1       6       9       0       1       0       0       0       0       0       1        6       11
Leprosy       0       0       0       0       0       2       0       2       0       0        0         4
Malaria       1       1       0       0     11       4       2       0       2       0        7         5
Measles       0       0       0       0       0       0       1       0       0       0        1         0
Meningococcal Infect.       1       0       0       0       2       1       2       1       0       0        5         2
Mumps       0       0       0       0       1       1       0       0       1       0        2         1
Pertussis       0       2       0       9       3       0       0       0       0       0        3       11
Pneumococcal Disease       9       3       0       2       9       5       1       0       0       2      19       12
Rotavirus       3     14       0       5       0     12       0       0       3       6        6       37
Rubella       1       0       0       0       1       1       0       0       0       0        2         1
Salmonella     22     20       6     11     39     50       3       8     17     18      87     107
Shigella     22       9       6       2       3       7       0       4       3       5      34       27
Syphilis     32     17       2       0       8     10       7     11     15     11      64       49
Tuberculosis       1       2       0       0     10       4       0       0       2       2      13         8
Typhoid       1       0       0       0       0       0       0       0       0       0        1         0
Yersiniosis       0       0       0       0       1       0       0       0       0       0        1         0
Total   491   221     64     51   440   337     68     79   120   143  1183     831
Points to note regarding notifications:
• Australian Encephalitis (MVE,) Amoebiasis, Botulism, Brucellosis, Chancroid, Cholera, Congenital Rubella Syndrome,
Diphtheria, Hepatitis C (incidence), Hepatitis E, Hydatid Disease, Legionnaires Disease, Leptospirosis, Listeriosis,
Lymphogranuloma venereum, Poliomyelitis, Typhus and Viral Haemorrhagic Fever are all notifiable but had "0"
notifications in this period.
• Rotavirus increased in early July 1997 and therefore is not reflected in this quarter.
• Arboviruses - The unusual amount and late rain in the Alice Springs and Barkly areas contributed to the highest RRV and
Barmah Forest notifications recorded since 1991.  Though not reflected in our notifications due to travel - 1 case of MVE
and 3 cases of Kunjin were acquired in these areas during this period.  Late rains in the Top End also showed higher
numbers in April to June than in previous years.
• Gonococcal disease in Darwin increased due to inclusion of positive results of tampon testing after 1/7/96 and possibly
wider PCR screening.  For Alice Spriings the increase is due to more screening including improved techniques for antenatal
specimen collection, and opportunistic STD testing.
• Gonococcal conjunctivitis increase shows the outbreak as reported in the first article.
• Hepatitis A - A major outbreak in a child care centre in Alice Springs (12 cases) accounts for the increase in notified cases
for this quarter.  The increase in Katherine is less clear as all were sporadic unrelated cases except for one family which
resulted in 4 cases.
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Notified cases of Vaccine Preventable Diseases in NT
by Report Date 1 April to 30 June 1997 and 1996
DISEASES       TOTAL No. cases among
children aged 0-5
years
   '97    '96    '97    '96
Congenital rubella syndrome        0       0       0       0
Diphtheria        0       0       0       0
Haemophilus influenzae type b        1       0       1       0
Hepatitis B      11       3       0       0
Measles        1       0       1       0
Mumps        2       1       0       0
Pertussis        3      11       1       2
Poliomyelitis, paralytic        0       0       0       0
Rubella        2       1       1       0
Tetanus        0       0       0       0
• Mumps is largely under-reported.
• Hepatitis B increase was across all regions
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MALARIA NOTIFICATIONS, NORTHERN TERRITORY
April to June 1997
Compiled by Peter Knibbs and Mervyn Fairley, CDC, Darwin
Seven notifications of malaria were received for the second quarter of 1997.  The following table
provides details about where the infection was thought to be acquired, the infecting agent and whether
chemoprophylaxis was used.
ORIGIN OF
INFECTION
REASON
EXPOSED
AGENT CHEMO-
PROPHY-
LAXIS
COMMENTS
PACIFIC
PNG Business visit P.vivax No Travels regularly between NT and PNG
PNG Holiday P.vivax Yes
PNG PNG resident P.falciparum Yes Vague history of chemoprophylaxis.  In
Darwin for Arafura Games.
ASIA/SE ASIA
Indonesia Illegal immigrant P.falciparum No Travelled by boat from Malaysia to
Kupang.
Indonesia Indonesian resident P.vivax No Indonesian fisherman detained in
Australian waters.
Indonesia Holiday P.vivax No On Roti for four days.  Son diagnosed
with malaria in Adelaide.
Indonesia Diving holiday P.falciparum Yes Symptoms developed 5 weeks after
return.
STAFF UPDATES
Sandy Thompson is the new medical officer
in the Population Health Unit in Alice Springs,
having most recently been working at
Macfarlane Burnet Centre for Medical research
in their Epidemiology and Social Research
Unit.  She has a wide range of interests in
public health, particularly in immunisation and
infectious diseases epidemiology.
Michael Howard recently joined the Sexual
Health Unit in Alice springs as the
Donovanosis Project Officer.  The project aims
to establish a donovanosis register, increase
notification rates and ensure individuals
receive effective treatment and follow-up.  He
has previously worked in Katherine and Utopia
as a Remote Area Nurse.
Angela Merianos has returned to her position
as head of Immunisation and Surveillance,
CDC Darwin, after spending 6 months working
on a hepatitis E project in Nepal.
Fay Johnston, who was acting in Angela’s
position has gone on 2 months leave and Tania
Wallace, TB/leprosy medical officer, CDC,
Darwin has recently commenced 3 months
maternity leave.  Sarah Huffam (formerly the
infectious diseases and microbiology registrar,
RDH) is filling in for Tania for the three
months.
